临床试验/ISRCTN13990511

ISRCTN13990511已完成2 期

Convalescent plasma for early Ebola virus disease in Sierra Leone: an open-label, non-randomized, controlled clinical trial

niversity of Liverpool0 个研究点目标入组 230 人开始时间: 2015年4月27日最近更新: 2023年5月29日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 230

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

2018 Other publications in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947131/ article on feasibility of donor recruitment (added 01/08/2019) 2021 Other publications in https://pubmed.ncbi.nlm.nih.gov/33505020/ (added 17/05/2023)

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•1. Persons of all ages and sex admitted to Ebola treatment units with confirmed Ebola virus disease
•2. Health care workers who experience a safety incident as a result of the intervention
•3. Survivors of Ebola virus disease who volunteer to donate plasma

排除标准

•1. Those for whom the intervention is contraindicated
•2. Those who are unresponsive (per AVPU) just prior to intervention
•3. Those for whom any intervention is considered futile

研究者

发起方

niversity of Liverpool

相似试验

PACTR201602001355272niversity of Liverpool130

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent PlasmaCovid-19

NCT04502472Inova Health Care Services109

Convalescent Plasma for Treatment of COVID-19Covid19

NCT04649879Joakim Dillner59

Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying StudyCOVID-19

NCT04384497Joakim Dillner10

Convalescent Plasma as Potential Therapy for Severe COVID-19 PneumoniaCovid19 Pneumonia

NCT04535063Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno200